Does Medicare cover Zepbound®? What to know about the GLP-1 Bridge program

GLP-1 medications like Zepbound® have changed how people and their doctors approach weight loss—but the price has always been a sticking point for many. Without insurance, Zepbound® can cost over $1,000 a month. And for people on Medicare, coverage has been off the table entirely. 

Federal law has barred Medicare from paying for weight loss medications since 2006, leaving millions of older adults and people with disabilities without a covered option, no matter how much their health might benefit from treatment.

That’s starting to change. If you’re on Medicare and wondering whether it covers Zepbound® for weight loss, the short answer is still: not under standard Medicare. But starting July 1, 2026, a new pilot program called the Medicare GLP-1 Bridge will let eligible Medicare beneficiaries access Zepbound, Wegovy®, and Foundayo® for weight loss at a flat $50 per month copay.

That shift matters more than it might sound. The GLP-1 Bridge doesn’t change the underlying law permanently—but it does open a door, at least for now, for people who couldn’t cover the cost on their own.

Here’s everything you need to know about what Medicare currently covers, how the new GLP-1 Bridge works, who qualifies, and what happens after the program ends.

What is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a short-term pilot program created by the Centers for Medicare & Medicaid Services (CMS). It was announced in December 2025 as a way to help people with Medicare Part D access GLP-1 weight loss medications at a lower cost. This is happening while the government figures out what longer-term coverage will look like.

The program runs from July 1, 2026, through December 31, 2027. It works separately from your regular Part D plan, so your plan doesn’t need to do anything special for you to be eligible.

Here are some of the main details:

• The only covered drugs: are Zepbound® KwikPen injections,Wegovy® injection and pills, and Foundayo® oral pill
• The copay is $50 per month, regardless of dosage—a fixed rate whether you’re on the starting dose or the highest maintenance dose.
• The program is available in all 50 states and U.S. territories.
• The $50 copay doesn’t count toward your Part D deductible or $2,100 annual out-of-pocket maximum.
• Low-income subsidy (Extra Help) doesn’t reduce the $50 copay. You pay the $50 regardless of whether you qualify for subsidies. 

What form of Zepbound is included under the Medicare GLP-1 Bridge?

Zepbound® (tirzepatide) is a bit of a confusing medication when it comes to price, because it has three different forms, and all three can have different price points now with the Medicare GLP-1 Bridge. 

Zepbound comes as a single-dose pen that can be gotten for full price or as low as $25 with commercial insurance coverage. It also comes as a vial or multi-dose KwikPen that is offered through Lilly Direct’s discounted cash-pay program for people not using insurance.  

Only the Zepbound® KwikPen formulation is covered under the Medicare GLP-1 Bridge. The single-dose pen and single-dose vial versions are not included.

The key details about the Kwikpens are: 

• Multi-dose autoinjector pen, with one pen containing 4 weekly doses (about a one-month supply)
• Available in the following doses:
  • 2.5 mg
  • 5 mg
  • 7.5 mg
  • 10 mg
  • 12.5 mg
  • 15 mg
• Eligible members pay the Bridge copay instead of retail cash pricing
• Zepbound® KwikPens are also sold through LillyDirect at cash-pay prices, for $299 to $449, depending on the dose.

The two versions that aren’t covered under Bridge are: 

1. Zepbound® single-dose pens: These are disposable, one-time-use injection pens that contain a single weekly dose per pen.

• Sold in cartons containing 4 pens (one month supply)
• Available through standard retail and commercial pharmacy channels
• The retail price is about $1080 per month or more, but can be as low as $25 a month with insurance and the Zepbound Savings Card. Read more: Zepbound® costs in 2026: With and without insurance coverage

2. Zepbound® single-dose vials: These are single-use medication vials designed for self-injection with a syringe.

• Only sold through LillyDirect at cash-pay pricing, for $299 to $449, depending on the dose.

Who’s eligible to get Zepbound through the Medicare GLP-1 Bridge?

To qualify, you must be enrolled in a Medicare Part D plan (either a standalone Part D plan or a Medicare Advantage plan with drug coverage). After that, eligibility comes down to your BMI and health history at the time you started GLP-1 therapy—not necessarily your BMI today. That means if you’ve already lost weight on a GLP-1, your provider can confirm that you met the criteria when you first started. 

Qualification comes down to three tiers based on BMI, sometimes combined with a related health condition.

• BMI ≥35: You automatically qualify with no additional diagnosis required.
• BMI ≥30: You qualify if you also have heart failure with preserved ejection fraction (a type of heart failure where the heart pumps normally but the muscle is stiff), uncontrolled hypertension (blood pressure above 140/90 despite taking two blood pressure medications), or chronic kidney disease stage 3a or above.
• BMI ≥27: You qualify if you also have prediabetes (per ADA guidelines), a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

Here’s how those three tiers break down:

Category	BMI requirement	Additional conditions
Category 1	BMI ≥35	No additional conditions required — BMI alone qualifies
Category 2	BMI ≥30	BMI of 30+ with heart failure, uncontrolled hypertension, or chronic kidney disease
Category 3	BMI ≥27	BMI of 27+ with prediabetes (per ADA guidelines); previous heart attack; previous stroke; or symptomatic peripheral artery disease

One important note on timing: the criteria need to be met at the time you started GLP-1 therapy, not today. For example, if you started a GLP-1 in September 2024 with a BMI of 37 but now have a BMI of 34, your provider should confirm that you met the BMI ≥35 threshold when you began. This means many people already on GLP-1s may still qualify.

Some Medicare plan types don’t qualify. People enrolled in private fee-for-service plans, PACE organizations, and certain other plan types aren’t eligible for the Bridge unless they’re also enrolled in a standalone Part D plan.

What conditions does the GLP-1 bridge program not cover?

The GLP-1 Bridge is for weight management only. A few key things it doesn’t cover are:

• If you’re already getting a GLP-1 covered through Part D for a Medicare-approved use—like diabetes, cardiovascular risk reduction, or sleep apnea—you’ll stay on your regular plan for that. You can’t switch that same prescription to the Bridge.
• Zepbound’s® single-dose vial and single-dose pen formulations are not included—only the KwikPen. 
• Low-income subsidy (Extra Help) cost-sharing assistance does not apply to the GLP-1 Bridge copay. For someone on Social Security paying $5 or $10 for other prescriptions, $50/month is a meaningful additional cost.
• The $50 copay does not count toward your Part D deductible or annual $2,100 out-of-pocket maximum.

Does Medicare cover Zepbound® for sleep apnea?

Zepbound is FDA-approved to treat moderate-to-severe OSA in adults with obesity. Because this approval is tied to sleep apnea—not weight loss—some Medicare Part D plans may cover it under your regular prescription drug benefit.

Coverage varies by plan and may require a prior authorization, documentation of your OSA diagnosis, and proof that certain clinical criteria are met to be eligible for the prescription. 

If your provider prescribes Zepbound for sleep apnea, the prescription goes through your regular Medicare Part D plan—not the Medicare GLP-1 Bridge. That means your cost will depend on your specific plan’s coverage and copay structure, rather than the Bridge’s $50 copay.

Does the medicare GLP-1 Bridge cover other GLP-1s?

The GLP-1 Bridge specifically covers Wegovy®, Zepbound® KwikPen, and Foundayo®. Standard Medicare Part D might cover other GLP-1s for non-weight-loss diagnoses like diabetes, OSA, and heart disease. Here’s how the full landscape looks:

Medication (brand name)	FDA approval(s)	Medicare coverage?*
Zepbound®	Weight management; obstructive sleep apnea (OSA)	KwikPen: Covered under GLP-1 Bridge for eligible beneficiaries; Not covered for weight loss under standard Medicare  Vial: Not covered for weight loss under standard Medicare or Bridge Single-use pen: May be covered for OSA under Part D; Not covered for weight loss
Ozempic® Ozempic pill®	Type 2 diabetes	May be covered for diabetes
Wegovy® injection  Wegovy® pill	Injection: Weight management, heart disease, and MASH Pill: Weight management	Injection: Not covered for weight loss alone; may be covered for heart disease or MASH Pill: Covered under GLP-1 Bridge for eligible beneficiaries
Mounjaro®	Type 2 diabetes	May be covered for diabetes
Foundayo®	Weight management (oral pill)	Covered under GLP-1 Bridge for eligible beneficiaries
Victoza®	Type 2 diabetes, heart disease	May be covered for diabetes or heart disease
Saxenda®	Weight management	Not covered for weight loss
Trulicity®	Type 2 diabetes	May be covered for diabetes

Coverage depends on your specific Part D or Medicare Advantage plan’s formulary, prior authorization requirements, and step therapy policies. Always verify with your plan.

Read more: Does Medicare cover weight loss drugs?

What conditions does the medicare GLP-1 Bridge cover?

The GLP-1 Bridge covers Wegovy®, Zepbound® (KwikPens only), and Foundayo® specifically for weight loss and weight maintenance. To qualify, the medication needs to be used alongside ongoing lifestyle changes—things like structured nutrition support and physical activity—consistent with each drug’s FDA-approved label.

The health conditions that qualify you at the lower BMI thresholds are:

• Heart failure with preserved ejection fraction (required for BMI ≥30 pathway)
• Uncontrolled hypertension despite two antihypertensive medications (BMI ≥30 pathway)
• Chronic kidney disease stage 3a or above (BMI ≥30 pathway)
• Prediabetes, as defined by American Diabetes Association guidelines (BMI ≥27 pathway)
• Previous heart attack (myocardial infarction) (BMI ≥27 pathway)
• Previous stroke (BMI ≥27 pathway)
• Symptomatic peripheral artery disease (BMI ≥27 pathway)

What changes on July 1, 2026?

July 1, 2026, is when the Medicare GLP-1 Bridge goes live. Before then, standard Medicare rules still apply: weight loss medications aren’t covered, and GLP-1s are only accessible through Medicare if they’re prescribed for a condition Medicare does cover—like diabetes, heart disease, or OSA.

Starting July 1:

• Eligible Medicare Part D enrollees can access Zepbound KwikPen®, Wegovy® injections and pills,  and Foundayo® pills for weight loss at a flat $50/month copay.
• Your provider doesn’t need to be enrolled in Medicare to prescribe one of these medications or request prior authorization for the Bridge.

One important caveat about what comes next: the BALANCE Model—the longer-term program that was supposed to take over in January 2027—didn’t happen. Not enough insurers signed on, so CMS extended the GLP-1 Bridge through December 2027 instead. Beyond December 2027, there’s no confirmed plan for what happens to Medicare coverage of weight loss medications.

What if I don’t qualify for the Medicare GLP-1 Bridge?

If you don’t qualify for the GLP-1 Bridge, you still have options to bring costs down. The most affordable way would be to get it through Lilly Direct for $299-449, depending on dose.

Read more: Zepbound cost without insurance: What to expect in 2026

Frequently asked questions about Medicare coverage for Zepbound®

How do I get Zepbound® if I have Medicare?

Starting July 1, 2026, if you’re enrolled in a Medicare Part D plan and meet the eligibility criteria, your provider requests prior authorization through the GLP-1 Bridge system. Once approved, you pick up Zepbound’s KwikPen at the pharmacy and pay a $50 copay. If you take Zepbound for sleep apnea, that stays through your regular Part D plan.

How much does Zepbound® cost under Medicare?

Under the GLP-1 Bridge, you pay a flat $50 per month for the Zepbound® KwikPen, no matter what dose you’re on. That’s a significant drop compared to a list price of around $1,087 per month and LillyDirect vial pricing of $299–$449 per month. Without the Bridge, Medicare doesn’t cover Zepbound for weight loss—though it may cover it under Part D for obstructive sleep apnea, depending on your plan.

What diagnosis will cover Zepbound®?

Under the GLP-1 Bridge, Zepbound® is covered for weight management with a qualifying BMI and, in some cases, a related health condition like prediabetes, heart disease history, or kidney disease. Under standard Medicare Part D, Zepbound may be covered when prescribed for obstructive sleep apnea (OSA). It isn’t covered under standard Medicare for weight loss alone.

Does Medicare cover Wegovy® or Zepbound®?

It depends on what they are prescribed for. The Medicare GLP-1 Bridge program (launching July 1, 2026) will cover Zepbound KwikPen and Wegovy (injection and pill) for weight loss at $50/month for eligible people. Wegovy may also be covered under standard Medicare Part D when prescribed for cardiovascular risk reduction or MASH. Zepbound may be covered under Part D when prescribed for obstructive sleep apnea.

Does standard Medicare Part D cover Zepbound®?

Not for weight loss under standard Part D rules—federal law excludes medications prescribed solely for weight management. Part D may cover Zepbound® for obstructive sleep apnea, subject to your plan’s covered list, prior authorization, and likely step therapy. Starting July 1, 2026, the GLP-1 Bridge provides separate (non-Part D) coverage of the Zepbound® KwikPen for weight loss at $50/month.

Does Medicare cover Zepbound® for heart disease?

No Zepbound® (tirzepatide) doesn’t have FDA approval for heart disease risk reduction—that approval belongs to Wegovy® (semaglutide). That means Wegovy may be covered under Medicare Part D for heart disease, but Zepbound® wouldn’t. That said, Zepbound® may still be covered under the GLP-1 Bridge if your health history includes something like a prior heart attack or stroke, which can qualify you under the BMI ≥27 tier.

The bottom line: Medicare will cover Zepbound® for many under the GLP-1 Bridge program temporariliy

Medicare still doesn’t cover weight loss medications as a standard benefit—that hasn’t changed. But the Medicare GLP-1 Bridge, launching July 1, 2026, is a real change for a lot of people. If you qualify, it puts Zepbound® KwikPen, Wegovy®, and Foundayo® within reach at $50/month—a fraction of what they’d cost otherwise.

The program runs through December 2027, and what comes after is still an open question. The BALANCE Model—which was supposed to be the longer-term solution—didn’t get off the ground. In the meantime, if you’re on Medicare and thinking about a GLP-1 for weight loss, it’s worth asking your provider whether you qualify for the Bridge before July 1.

And if you’re already on a GLP-1 through Part D for diabetes, heart disease, or sleep apnea, that coverage stays in place. It’s always a good idea to check with your plan on what’s covered, what needs prior authorization, and what your actual out-of-pocket cost will be.